Work

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer

Year: 2021

Type: article

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2021.07.103

Authors: J.R. Bellon, N. Tayob, H.J. Burstein, A. Partridge, M.K. Demeo, J. Tralins, D.D. Yang, C. Dang, S.J. Isakoff, D. Yardley, V. Valero, E. Winer, I. Krop, S. Tolaney

Institutions: Dana-Farber Brigham Cancer Center, Dana-Farber Cancer Institute, Harvard University, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Tennessee Oncology, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3208671732

FWCI: 0.1

Cites:

Cited by: 1

Related to: 10